Medication Monitor



SORT BY:      Most Recent      Most Viewed     
List-View      Table-View
Generic Name (Trade Name—Company)
Notes
  • May 27, 2011

    Uses:

    Treatment of fecal incontinence in adult patients who have failed previous therapies such as modifications in diet, fiber therapy, or antimotility medications 

    Solesta 1 mL injectable gel consists of dextranomer microspheres (50 mg/mL) and stabilized sodium hyaluronate (15 mg/mL) in a phosphate-buffered 0.9% sodium chloride solution. It is injected into the deep submucosal layer in the proximal part of the high pressure zone of the anal canal. A total of four submucosal injections are administered at each treatment session. The injections are designed to build up tissue in that area so that the opening of the anus narrows allowing patients to have better control of their muscles. Only physicians experienced in performing anorectal procedures and who have successfully completed the Solesta injection procedure training program can administer the gel.

     

  • May 23, 2011

    Uses:

    Treatment of chronic hepatitis C genotype 1 infection

    Telaprevir is another oral agent approved by FDA for the treatment of chronic hepatitis C genotype 1 infection in adult patients with compensated liver disease, including those with cirrhosis. As with boceprevir, it must be given in combination with peginterferon alfa and ribavirin and can be used in patients who are previously untreated or those who have failed previous interferon and ribavirin therapy. Telaprevir’s mechanism of action is identical to boceprevir. The recommended dose is 750 mg (two 375-mg tablets) given orally three times daily (approximately every 7 to 9 hours) with food. It is given in combination with peginterferon alfa and ribavirin for the first 12 weeks. When added to peginterferon alfa and ribavirin, sustained viral response rates was as high as 79% in trials.

  • May 20, 2011

    Uses:

    Treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease

    Sunitinib is also approved for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumor (GIST) after disease progression with imatinib (Gleevec—Novartis) or in those with GIST intolerant to imatinib. Data from the SUN 111 trial showed that patients with unresectable pancreatic NET treated with sunitinib had a clinically significant improvement in progression-free survival compared with placebo (10.2 mo vs. 5.4 mo). An objective response rate of 9.3% was also observed in the sunitinib group, while no objective response occurred in the placebo group. The recommended dose for pancreatic NET is 37.5 mg once daily without a scheduled off-treatment period. 

     

  • May 20, 2011

    Uses:

    Treatment of HIV-1 in treatment-naive adults 

    Rilpivirine is the newest nonnucleoside reverse transcriptase inhibitor (NNRTI) for use in combination with other antiretroviral agents in treatment-naive adults. The recommended dose is one 25-mg tablet once daily with a meal. Approval was based on 48-week data from two Phase III trials and 96-week data from a Phase IIb trial that showed efficacy comparable to regimens that added efavirenz (Sustiva—Bristol-Myers Squibb). The most common adverse events of at least moderate to severe intensity were depression, insomnia, headache, and rash.

     

  • May 17, 2011

    Uses:

    Short-term management (up to 5 d) of moderate to moderately severe pain that requires analgesia at the opioid level 

    This new formulation of ketorolac is rapidly absorbed through the nasal mucosa, achieving peak blood levels as quickly as an I.M. injection of the drug. The recommended dose for patients younger than 65 years of age is one spray in each nostril (total dose 31.5 mg) every 6 to 8 hours, up to a maximum daily dose of 126 mg (four doses). For those who are at least 65 years of age, renally impaired, or who weigh less than 50 kg, the recommended dose is one spray in one nostril (total dose: 15.75 mg) every 6 to 8 hours up to a maximum daily dose of 63 mg (four doses). The spray will be marketed in a bottle containing eight sprays, with each spray containing 15.75 mg of ketorolac. The spray bottle needs to be discarded within 24 hours of taking the first dose, even if active drug remains in the container. 

     

     

Pages